Researchers at Flinders University in Australia found non-small-cell lung cancer patients given atezolizumab who had a BMI of 25 or more had up to a 32 per cent better chance of surviving.
Nanostics and Protean partner to offer CDX Prostate risk score as a diagnostic tool to men suspected of having aggressive prostate cancer in the USA.
Dr. Tony Magliocco of the Moffit Cancer Center joins us to discuss the indepensible role of pathologists in precision medicine and the importance of technology…
Anthony Magliocco, MD is a cancer expert with over 30 years of experience.In this video he explains why someone might be diagnosed with a ‘cancer…
Protean and Roche have created a novel project to accelerate access to precision oncology for community based oncology programs.
New research suggests stars in the Milky Way give off infrared heat expected from Dyson spheres, which physicist Freeman Dyson theorized could be created by…
Cancer Informant is a podcast made to inform cancer patients and their loved ones about their options for cancer testing and treatment. Dr. Tony Magliocco…
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, launched the Aventa FusionPlus test for patients with solid cancers.
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
